NCT04818229View on ClinicalTrials.gov

A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

March 20, 2022

Study Completion Date

March 30, 2022

Conditions
Autoimmune Diseases
Interventions
DRUG

CBP-307

CBP-307 capsules oral administration.

DRUG

Placebo-matched CBP-307

Placebo-matched CBP-307 capsules oral administration.

DRUG

Moxifloxacin (Avelox)

Moxifloxacin tablets oral administration。

DRUG

Placebo-matched Moxifloxacin

Placebo-matched Moxifloxacin tablets oral administration.

Trial Locations (2)

5000

CMAX, Adelaide

33014

Clinical Pharmacology of Miami (CPMI), LLC, Hialeah

All Listed Sponsors
lead

Connect Biopharma Australia Pty Ltd

INDUSTRY